SY 4798
Alternative Names: SY-4798Latest Information Update: 23 Sep 2025
At a glance
- Originator Shouyao Holdings
- Class Antineoplastics; Small molecules
- Mechanism of Action Type 4 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Liver cancer
Most Recent Events
- 23 Sep 2025 Phase-I clinical development in Liver cancer (Late-stage disease, Second-line therapy or greater) is underway in China (PO) (NCT05498519) (Shouyao Holdings pipeline, September 2025)
- 28 May 2024 No recent reports of development identified for phase-I development in Liver-cancer (Late-stage disease, Second-line therapy or greater) in China (PO, Tablet)
- 15 Apr 2021 Phase-I clinical trials in Liver cancer(Late-stage disease, Second-line therapy or greater) in China (PO) (NCT05498519)